An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F22%3AN0000004" target="_blank" >RIV/00023728:_____/22:N0000004 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/22:10440494 RIV/00216208:11110/22:10440494 RIV/00216208:11150/22:10440494 RIV/00179906:_____/22:10440494

Result on the web

<a href="https://doi.org/10.1093/ehjcvp/pvab052" target="_blank" >https://doi.org/10.1093/ehjcvp/pvab052</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ehjcvp/pvab052" target="_blank" >10.1093/ehjcvp/pvab052</a>

Result language

angličtina

Original language name

An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries

Original language description

Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

<a href="/en/project/NV18-01-00161" target="_blank" >NV18-01-00161: Atherosclerosis and cardiovascular risk in selected rheumatic diseases</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European heart journal. Cardiovascular pharmacotherapy.

ISSN

2055-6837

e-ISSN

2055-6845

Volume of the periodical

8

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

539-548

UT code for WoS article

000755901700001

EID of the result in the Scopus database

2-s2.0-85117160897